یوپاداسیتینیب (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "یوپاداسیتینیب" in Persian language version.

refsWebsite

Global rank Persian rank

22web.archive.org

1^st place

4fda.gov

447^th place

382^nd place

3tga.gov.au

3,984^th place

1,143^rd place

2europa.eu

68^th place

179^th place

2abbvie.com

low place

2nih.gov

4^th place

5^th place

1drugs.com

399^th place

104^th place

1canada.ca

1,712^th place

2,923^rd place

1hres.ca

low place

1hpfb-dgpsa.ca

low place

1medicines.org.uk

3,823^rd place

1,188^th place

1doi.org

2^nd place

1semanticscholar.org

11^th place

52^nd place

1europeanpharmaceuticalreview.com

low place

1labiotech.eu

low place

1thepharmaletter.com

low place

1seekingalpha.com

5,344^th place

low place

1yahoo.com

38^th place

109^th place

1prnewswire.com

406^th place

1,024^th place

abbvie.com

news.abbvie.com

"AbbVie Receives FDA Approval of Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis" (Press release). AbbVie. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
"Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis" (Press release). AbbVie. Archived from the original on 7 February 2023. Retrieved 7 February 2023.

canada.ca

health-products.canada.ca

"Rinvoq Product information". Health Canada. 25 April 2012. Archived from the original on 30 May 2022. Retrieved 29 May 2022.

doi.org

Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA (December 2016). "Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Participants with Rheumatoid Arthritis". Clinical Pharmacokinetics. 55 (12): 1547–1558. doi:10.1007/s40262-016-0419-y. PMID 27272171. S2CID 39036534.

drugs.com

"Upadacitinib (Rinvoq) Use During Pregnancy". Drugs.com. 23 September 2019. Archived from the original on 18 March 2020. Retrieved 17 March 2020.

europa.eu

ema.europa.eu

"Rinvoq EPAR". European Medicines Agency (EMA). 16 October 2019. Archived from the original on 20 October 2020. Retrieved 29 April 2020.
"Rinvoq: EPAR – Public assessment report" (PDF). European Medicines Agency. 5 March 2020. Archived (PDF) from the original on 21 July 2020. Retrieved 21 July 2020.

europeanpharmaceuticalreview.com

"MHRA approves first oral advanced therapy for Crohn's disease". European Pharmaceutical Review. Archived from the original on 9 February 2023. Retrieved 9 February 2023.

fda.gov

"Drug Trials Snapshots: Rinvoq". U.S. Food and Drug Administration (FDA). 16 August 2019. Archived from the original on 5 August 2020. Retrieved 18 March 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves first oral treatment for moderately to severely active Crohn's disease". U.S. Food and Drug Administration (FDA). 18 May 2023. Archived from the original on 28 May 2023. Retrieved 2 June 2023. This article incorporates text from this source, which is in the public domain.
"Advancing Health Through Innovation: New Drug Therapy Approvals". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023. Retrieved 10 February 2023.

accessdata.fda.gov

"Drug Approval Package: Rinvoq". U.S. Food and Drug Administration (FDA). 12 September 2019. Archived from the original on 30 March 2021. Retrieved 29 April 2020.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Regulatory Decision Summary for Rinvoq". Drug and Health Products Portal. 21 July 2023. Retrieved 1 April 2024.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Rinvoq". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.

labiotech.eu

Cornall, Jim (3 February 2023). "UK approval for AbbVie Crohn's disease drug". Labiotech.eu. Archived from the original on 9 February 2023. Retrieved 9 February 2023.

medicines.org.uk

"Rinvoq 15 mg prolonged-release tablets - Summary of Product Characteristics (SmPC)". (emc). 1 March 2020. Archived from the original on 27 August 2021. Retrieved 22 August 2020.

nih.gov

dailymed.nlm.nih.gov

"Rinvoq- upadacitinib tablet, extended release". DailyMed. 1 March 2020. Archived from the original on 27 August 2021. Retrieved 29 April 2020.

pubmed.ncbi.nlm.nih.gov

Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA (December 2016). "Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Participants with Rheumatoid Arthritis". Clinical Pharmacokinetics. 55 (12): 1547–1558. doi:10.1007/s40262-016-0419-y. PMID 27272171. S2CID 39036534.

prnewswire.com

"U.S. FDA Approves Rinvoq (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults" (Press release). AbbVie. 18 May 2023. Archived from the original on 26 May 2023. Retrieved 2 June 2023 – via PR Newswire.

seekingalpha.com

"Stock Market Insights". Seeking Alpha. 17 April 2023. Archived from the original on 21 April 2023. Retrieved 21 April 2023.

semanticscholar.org

api.semanticscholar.org

Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA (December 2016). "Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Participants with Rheumatoid Arthritis". Clinical Pharmacokinetics. 55 (12): 1547–1558. doi:10.1007/s40262-016-0419-y. PMID 27272171. S2CID 39036534.

tga.gov.au

"AusPAR: Upadacitinib". Therapeutic Goods Administration (TGA). 25 August 2021. Archived from the original on 4 September 2021. Retrieved 4 September 2021.
"Rinvoq (Abbvie Pty Ltd)". Archived from the original on 9 November 2022. Retrieved 9 November 2022.
"Rinvoq (Abbvie Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 18 March 2023. Retrieved 9 April 2023.

thepharmaletter.com

"EC approval of Rinvoq in Crohn's disease". www.thepharmaletter.com. Archived from the original on 21 April 2023. Retrieved 21 April 2023.

web.archive.org

"Upadacitinib (Rinvoq) Use During Pregnancy". Drugs.com. 23 September 2019. Archived from the original on 18 March 2020. Retrieved 17 March 2020.
"AusPAR: Upadacitinib". Therapeutic Goods Administration (TGA). 25 August 2021. Archived from the original on 4 September 2021. Retrieved 4 September 2021.
"Rinvoq (Abbvie Pty Ltd)". Archived from the original on 9 November 2022. Retrieved 9 November 2022.
"Rinvoq (Abbvie Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 18 March 2023. Retrieved 9 April 2023.
"Rinvoq Product information". Health Canada. 25 April 2012. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
"Summary Basis of Decision (SBD) for Rinvoq". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
"Rinvoq 15 mg prolonged-release tablets - Summary of Product Characteristics (SmPC)". (emc). 1 March 2020. Archived from the original on 27 August 2021. Retrieved 22 August 2020.
"Rinvoq- upadacitinib tablet, extended release". DailyMed. 1 March 2020. Archived from the original on 27 August 2021. Retrieved 29 April 2020.
"Rinvoq EPAR". European Medicines Agency (EMA). 16 October 2019. Archived from the original on 20 October 2020. Retrieved 29 April 2020.
"Rinvoq: EPAR – Public assessment report" (PDF). European Medicines Agency. 5 March 2020. Archived (PDF) from the original on 21 July 2020. Retrieved 21 July 2020.
"Drug Trials Snapshots: Rinvoq". U.S. Food and Drug Administration (FDA). 16 August 2019. Archived from the original on 5 August 2020. Retrieved 18 March 2020. This article incorporates text from this source, which is in the public domain.
"Drug Approval Package: Rinvoq". U.S. Food and Drug Administration (FDA). 12 September 2019. Archived from the original on 30 March 2021. Retrieved 29 April 2020.
"AbbVie Receives FDA Approval of Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis" (Press release). AbbVie. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
"Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis" (Press release). AbbVie. Archived from the original on 7 February 2023. Retrieved 7 February 2023.
"MHRA approves first oral advanced therapy for Crohn's disease". European Pharmaceutical Review. Archived from the original on 9 February 2023. Retrieved 9 February 2023.
Cornall, Jim (3 February 2023). "UK approval for AbbVie Crohn's disease drug". Labiotech.eu. Archived from the original on 9 February 2023. Retrieved 9 February 2023.
"EC approval of Rinvoq in Crohn's disease". www.thepharmaletter.com. Archived from the original on 21 April 2023. Retrieved 21 April 2023.
"Stock Market Insights". Seeking Alpha. 17 April 2023. Archived from the original on 21 April 2023. Retrieved 21 April 2023.
"AbbVie Announces European Commission Approval of Rinvoq (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease". Yahoo Finance. 17 April 2023. Archived from the original on 21 April 2023. Retrieved 21 April 2023.
"FDA approves first oral treatment for moderately to severely active Crohn's disease". U.S. Food and Drug Administration (FDA). 18 May 2023. Archived from the original on 28 May 2023. Retrieved 2 June 2023. This article incorporates text from this source, which is in the public domain.
"U.S. FDA Approves Rinvoq (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults" (Press release). AbbVie. 18 May 2023. Archived from the original on 26 May 2023. Retrieved 2 June 2023 – via PR Newswire.
"Advancing Health Through Innovation: New Drug Therapy Approvals". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023. Retrieved 10 February 2023.

yahoo.com

finance.yahoo.com

"AbbVie Announces European Commission Approval of Rinvoq (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease". Yahoo Finance. 17 April 2023. Archived from the original on 21 April 2023. Retrieved 21 April 2023.